Projects per year
Personal profile
Area of Expertise
The main focus of my research is to discover and develop bioactive natural products from microorganisms as drugs or drug leads for the treatment of cancer, infectious diseases, or other human medical conditions. In addition, I recently initiated a collaborative project for the engineering of novel oncolytic virus for cancer chemoimmunotherapy.
Key words: anti-aging, anti-cancer, anti-infective, crowd-sourcing, crowd-funding, drug discovery, drug development, natural product, synthetic biology, chemoimmunotherapy, contract service
Key words: anti-aging, anti-cancer, anti-infective, crowd-sourcing, crowd-funding, drug discovery, drug development, natural product, synthetic biology, chemoimmunotherapy, contract service
Education/Academic qualification
BS in Microbiology, Huazhong Agricultural University
MS in Phytochemistry, Institute of Botany of the Chinese Academy of Sciences
PhD in Botany & Microbiology, Michigan State University
Fingerprint
Dive into the research topics where Yiqiang (Eric) Cheng is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 7 Finished
-
High-Resolution Tandem Mass Spectrometer for Advanced Biomolecular Research
Prokai, L., Forster, M. & Cheng, Y.
27/01/17 → 31/01/18
Project: Research
-
Discover and Engineer New Histone Deacetylase Inhibitors as Anticancer Agents
NCI: National Cancer Institute
1/06/13 → 31/05/15
Project: Research
-
Discover and Engineer New Histone Deacetylase Inhibitors as Anticancer Agents
Cheng, Y. (., CHENG, Y., CHENG, Y., CHENG, Y. & CHENG, Y.
1/08/10 → 30/11/15
Project: Research
-
Discover and Engineer New Histone Deacetylase Inhibitors as Anticancer Agents
Cheng, Y., CHENG, Y., CHENG, Y., CHENG, Y., CHENG, Y. & CHENG, Y.
1/08/10 → 30/11/15
Project: Research
Research output
-
Corrigendum to: Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment [Surgery. 2020 Jan;167(1):189-196. doi: 10.1016/j.surg.2019.05.092. Epub 2019 Oct 16.PMID: 31629542] (Surgery (2020) 167(1) (189–196), (S0039606019305835), (10.1016/j.surg.2019.05.092))
Guenter, R., Aweda, T., Carmona Matos, D. M., Jang, S., Whitt, J., Cheng, Y. Q., Liu, X. M., Chen, H., Lapi, S. E. & Jaskula-Sztul, R., Jul 2021, In: Surgery (United States). 170, 1, p. 351 1 p.Research output: Contribution to journal › Comment/debate
Open Access -
Determination of metformin bio-distribution by LC-MS/MS in mice treated with a clinically relevant paradigm
Chaudhari, K., Wang, J., Xu, Y., Winters, A., Wang, L., Dong, X., Cheng, E. Y., Liu, R. & Yang, S. H., Jun 2020, In: PLoS ONE. 15, 6, e0234571.Research output: Contribution to journal › Article › peer-review
Open Access16 Scopus citations -
Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment
Guenter, R., Aweda, T., Carmona Matos, D. M., Jang, S., Whitt, J., Cheng, Y. Q., Liu, X. M., Chen, H., Lapi, S. E. & Jaskula-Sztul, R., Jan 2020, In: Surgery (United States). 167, 1, p. 189-196 8 p.Research output: Contribution to journal › Article › peer-review
11 Scopus citations -
Origin and bioactivities of thiosulfinated FK228
Liu, X., Currens, G. C., Xue, L. & Cheng, Y. Q., 2019, In: MedChemComm. 10, 4, p. 538-542 5 p.Research output: Contribution to journal › Article › peer-review
-
Pulmonary carcinoid surface receptor modulation using histone deacetylase inhibitors
Guenter, R. E., Aweda, T., Matos, D. M. C., Whitt, J., Chang, A. W., Cheng, E. Y., Liu, X. M., Chen, H., Lapi, S. E. & Jaskula-Sztul, R., Jun 2019, In: Cancers. 11, 6, 767.Research output: Contribution to journal › Article › peer-review
Open Access10 Scopus citations